RESEARCH ARTICLE

REVISED Quadriceps muscle power and optimal shortening velocity are inversely related to angiotensin converting enzyme activity in older men [version 2; peer review: 2 approved]

Joanna Kostka ¹, Joanna Sikora², Agnieszka Guligowska³, Tomasz Kostka³

¹Department of Gerontology, Medical University of Lodz, Lodz, Poland

²Laboratory of Bioanalysis, Department of Pharmaceutical Chemistry, Drug Analysis and Radiopharmacy, Medical University of Lodz, Lodz, Poland

³Department of Geriatrics, Healthy Ageing Research Centre, Medical University of Lodz, Lodz, Poland

v2 First published: 05 Mar 2021, 10:184
<https://doi.org/10.12688/f1000research.51208.1>
 Latest published: 09 Jun 2021, 10:184
<https://doi.org/10.12688/f1000research.51208.2>

Abstract

Background: Methods which potentially could prevent age-related loss of muscle mass and function are still being sought. There are various attempts to use pharmacological agents to prevent loss of muscle mass, but the effectiveness of many of them still needs to be confirmed. One of the promising therapeutics are Angiotensin Converting Enzyme Inhibitors (ACEIs) and lowering of serum ACE activity. The goal of this study was to assess if taking Angiotensin Converting Enzyme Inhibitors (ACEI) and other angiotensin system blocking medications (ASBMs) can modify muscle performance in older men as well as to assess the association of serum ACE activity with muscle strength, power, muscle contraction velocity and functional performance.

Methods: Seventy-nine older men took part in the study. Muscle function was assessed with hand grip strength, maximum power relative to body mass (Pmax) and optimal shortening velocity (Uopt) of the knee extensor muscles. Anthropometric data, ACE activity and functional performance were also measured.

Results: Negative correlations between ACE activity and Pmax ($\rho = -0.29$, $p = 0.04$) as well as Uopt ($\rho = -0.31$, $p = 0.03$) in a group of patients not taking ACEI and between ACE activity and Uopt ($\rho = -0.22$, $p = 0.05$) in the whole group of men were found. Positive relationship between age and ACE activity was demonstrated ($\rho = 0.26$, $p = 0.02$). Age was the only selected variable in the multiple regression analyses to determine both Pmax and Uopt.

Conclusions: Serum ACE activity negatively associates to muscle power and muscle contraction velocity. The issues related to the impact of taking ACEI on the maintenance of muscle function and

Open Peer Review

Approval Status

	1	2
version 2 (revision) 09 Jun 2021		 view
version 1 05 Mar 2021	 view	 view

1. **Ida Wiszomirska** , Józef Piłsudski
University of Physical Education, Warsaw,
Poland

2. **Christophe A. Hautier** , Université Claude
Bernard Lyon 1, Villeurbanne, France

Any reports and responses or comments on the article can be found at the end of the article.

functional performance in older man require further studies.

Keywords

sarcopenia, muscle function, muscle strength, ageing, ACE inhibitors

Corresponding author: Joanna Kostka (joanna.kostka@umed.lodz.pl)

Author roles: **Kostka J:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Sikora J:** Investigation, Methodology, Resources, Writing – Original Draft Preparation; **Guligowska A:** Investigation, Resources, Writing – Original Draft Preparation; **Kostka T:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Methodology, Project Administration, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This study was funded by Medical University of Lodz (grant number: 503/6-077-01/503-61-002 for Department of Geriatrics).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2021 Kostka J *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Kostka J, Sikora J, Guligowska A and Kostka T. **Quadriceps muscle power and optimal shortening velocity are inversely related to angiotensin converting enzyme activity in older men [version 2; peer review: 2 approved]** F1000Research 2021, 10:184 <https://doi.org/10.12688/f1000research.51208.2>

First published: 05 Mar 2021, 10:184 <https://doi.org/10.12688/f1000research.51208.1>

REVISED Amendments from Version 1

All comments of the reviewers have been taken into account in the new version. The introduction of the article was supplemented with an attempt to justify the use of ACE inhibitors to maintain muscle mass and strength, while the discussion was supplemented with information on potential mechanisms related to the influence of ACE activity on the level of power and muscle contraction velocity. In the "Methods" section we have described in more detail the measurement of muscle power and muscle contraction velocity as well as the method of assigning patients to groups has been added.

We have also added "Limitations of the study" section and according to the reviewers suggestions we have slightly modified the conclusions.

Any further responses from the reviewers can be found at the end of the article

Introduction

Age-related sarcopenia, connected with deteriorating in muscle mass and function, is one of the most important factors determining functional status¹⁻³. That is why methods used to prevent age-related loss of muscle mass and function are still being sought. Physical activity especially with proper nutritional intervention may be potentially an effective management for sarcopenia⁴, but it is difficult to convince seniors to follow these recommendations. There are various attempts to use pharmacological agents to prevent loss of muscle mass, but the effectiveness of many of them still needs to be confirmed⁵. Taking Angiotensin Converting Enzyme Inhibitors (ACEI) is also being considered. ACEI are traditionally used among others as anti-hypertensive medications and in cardiovascular diseases or diabetic nephropathy treatment⁶, but there are also some hypotheses that using ACEI may modify muscle aging. For example, Onder *et al.*⁷ in a three-year observational study in a group of older women with hypertension and without congestive heart failure have shown that ACEI treatment may slow age-related decline in muscle strength. The authors of the article explain this effect with several mechanisms, such as: direct influence on mechanical and metabolic changes in muscles (shift of the myosin heavy chains of skeletal muscle toward the fatigue-resistant forms; increasing insulin sensitivity, glycogen storage and glucose uptake in skeletal muscle; reduction of kinin breakdown and, consequently, improved circulation and better glucose and amino acid uptake), suppression of inflammatory activation connected with muscle catabolism, beneficial effect on the nutritional status (inhibition of interleukin-6, which, among others, reduces appetite and, consequently, may cause malnutrition)⁷.

Taking ACEI as well as the ACE genotype with insertion (II) of allele in gene, is associated with lower serum ACE activity^{8,9}. There are suggestions that the ACE genotype type predisposes one to be successful in certain sports¹⁰. ACE is a basic component of renin-angiotensin system (RAS), which converts angiotensin I (ang I) in angiotensin II (ang II). Ang II may in turn influence muscle performance¹¹. Williams *et al.*¹² reported that circulating ACE activity was correlated

with isometric and isokinetic strength of quadriceps muscle strength in untrained man.

Even more important than muscle strength factor affecting functional performance in elderly population are muscle power and muscle contraction velocity^{1,2}. These factors are also more influenced by aging than muscle strength¹³. In addition to our recent research¹⁴, there are no reports on the effect of ACEI taking and serum ACE activity on muscle power and muscle contraction velocity in older population. In that study we have found association between serum ACE activity with optimal shortening velocity of quadriceps muscles in older women, but not with muscle strength and power. Because various sex-related factors can modify age-related muscle changes¹⁵, earlier reported sex-related differences in ACE activity¹⁶, as well as possible differences in absorption of medications (absorption in women may be slower due to reduced gastric acid secretion and gastrointestinal motility)¹⁷ we conducted similar study in the group of older men.

The goal of our study was to assess if taking ACEI can modify muscle performance in older man as well as to assess the association of serum ACE activity with muscle strength, power, muscle contraction velocity and functional performance

Methods

Subjects

Seventy-nine community-dwelling older men took part in the study. Participants were recruited through the local media by the Medical University of Lodz, Department of Geriatrics. The study included men aged ≥ 60 years, with the inclusion criteria of those with the ability to understand and execute commands, the ability to perform exercise testing, and those who signed the informed consent to participate in the study. Exclusion criteria were as follows: recent (<three months) diagnosis of myocardial infarction, stroke or orthopaedic surgery, cardiac contraindications to exercise tests, or lack of ability to perform tests because of motor system dysfunctions (limited range of motion, pain).

Ethical statement

The study was approved by the Bioethics Committee of the Medical University of Lodz No RNN/647/14/KB.

Protocol

Participants were asked to report to the Research Center in the morning (8–9 a.m.) on an empty stomach (at least 12 hours fasting), after a night's sleep. They were also asked to avoid smoking, drinking alcohol and taking heavy physical exertion for at least 12 hours. After fasting blood drawing and a light breakfast, a comprehensive assessment was carried out with each participant. The assessment included: interview (information on socio-economic status, current and previous illnesses, and current medication), anthropometric measurements, evaluation of muscle function (muscle strength, power and shortening velocity), as well as functional status assessment.

Based on the analysis of medications taken, men were assigned to the following groups: ACEI - if they were taking any

medications belonging to the ACEI group ($n = 26$) and to the non ACEI group - if they were not taking ACEI ($n = 53$). Similarly, if men were taking any drugs from the angiotensin system blocking medications (ASBMs) group, they were assigned to the ASBMs group ($n = 34$), if not, then to the non ASBMs group ($n = 45$)

Anthropometric data

Measurements of height, weight, and skinfold thickness (from: triceps, biceps, sub-scapula, and supra-ileum) were performed using standard methods. Body mass index – BMI ($\text{kg}\cdot\text{m}^{-2}$) was calculated and the percentage of body fat was estimated according to Durnin & Womersley¹⁸.

Muscle strength

The Jamar[®] hydraulic hand dynamometer (Sammons Preston Rolyan, Bolingbrook, Canada) was used for handgrip strength evaluation. The test was preceded by a demonstration of the researcher and performed twice (on both sides), with 30 second pauses between measurements. During the test, the participant was in a standing position, with shoulder in neutral position and elbow in flexion (90°) with no radioulnar deviation, and was encouraged to squeeze the device as hard as possible. Results were given in kilograms (kg). A better record for each hand separately was used for analysis¹⁹.

Maximum power (Pmax) and optimal shortening velocity (Uopt) of the knee extensor muscles

Muscle power and optimal shortening velocity evaluations were performed with especially prepared ergometer (Monark type 818E Stockholm, Sweden), during two 8-second attempts to pedal at the maximum possible speed with friction loads of $0.25 \text{ N}\cdot\text{kg}^{-1}$ and $0.35 \text{ N}\cdot\text{kg}^{-1}$ of body mass. Instantaneous pedaling velocity (U), force (F) and power output (P) were calculated each 5ms and then averaged over each downstroke period. The highest value of P (maximal short-term power – Pmax) and optimal shortening velocity (Uopt - velocity at which the power reaches a maximum value) were calculated from a 3rd order polynomial function. The methodology used in this measurement has been previously described in detail²⁰. Pmax was presented in relation to body mass ($\text{W}\cdot\text{kg}^{-1}$). Uopt was given in number of rotations per minute ($\text{rot}\cdot\text{min}^{-1}$).

Functional performance

Activities of Daily Living (ADL)²¹, the Lawton Instrumental Activities of Daily Living (IADL)²², and Timed Up & Go test (TUG)²³ were used to assess functional status of the participants.

ADL and IADL are scales based on questions concerning ability to perform basic and complex (instrumental) daily activities. ADL scale consists of six questions about activities such as eating, dressing, bathing, continence, toileting, and transferring. IADL contains questions about more complex activities enabling independent functioning, such as ability to use telephones, shopping, food preparation, cleaning, washing, use of public transport, responsibility for own medications, and ability to handle finances.

Timed Up & Go test is a simple and very popular functional test. It involves standing up from a sitting position, walking forth and back three meters, and sitting back on time. Time is given in seconds. After a familiarization test, this was performed twice and the better result was chosen for further analysis.

ACE activity evaluation

Fasting blood samples were collected from every man at the Research Center in the morning hours into vacuum tubes. The blood was centrifuged and then stored at -20°C until measurement. The reagents used and the method of analysis were described in our previous work¹⁴. Results were given in U/L.

Statistical analysis

The descriptive statistics are presented as mean $\pm$ standard deviation for data with a normal distribution, and for data without a normal distribution they were additionally shown as median (lower quartile - upper quartile). After the normality check, the one-way analysis of variance (ANOVA) or Mann-Whitney test (for quantitative data) and Chi² with Yates' correction test (for qualitative data - prevalence of diseases) were used for group comparison. Spearman's correlation coefficients were calculated to assess the relationships between numerical variables. To establish the most important determinants of Pmax and Uopt, the multiple regression analyses were made. For these analyses, ACE activity results were transformed logarithmically due to the non-normal distribution. Significance was set at a p value of $p < 0.05$.

Results

Baseline characteristics of the men taking and not taking ACEI as well as taking and not taking angiotensin system blocking medications (ASBMs) are shown in Table 1. Participants taking ACEI did not differ in terms of age, anthropometric indicators, education level, grip strength, muscle power, contraction velocity, and ADL results. Patients taking ACEI took more medications and were characterized by lower level of ACE in blood samples and lower IADL status. Men from both groups did not differ with regard to the prevalence of most diseases (ischemic heart disease, stroke, cancer, osteoporosis, COPD, heart failure, diabetes, myocardial infarction), but men taking ACEI more often suffered from hypertension ($p = 0.0003$).

Whereas participants taking ASBMs were more than two years older than subjects not taking ASBMs, they took more medications, had greater BMI, and did not differ in terms of majority of muscles function parameters (Pmax, Uopt, right handgrip strength), except for the left handgrip strength.

We have found a positive relationship between age and ACE activity in men not taking ACEI and in all studied patients. We have also found a negative correlation between ACE activity and Pmax (Figure 1) as well as with Uopt (Figure 2) in group of patients not taking ACEI and in the whole group of men (Table 2). Similar relationships were observed in group of men not taking any ASBMs – both Pmax (borderline

Table 1. Comparison of the results of the studied groups (ACEI vs non ACEI and ASBMs vs non ASBMs).

Characteristics	ACEI (n=26)	non ACEI (n=53)	ASBMs (n=34)	non ASBMs (n=45)
Age (years)	77.6±5.3 78.5 (75.0-82.0)	76.8±6.2 77.0 (72.0-80.0)	78.4±5.9	76.07±5.7
Body mass (kg)	82.3±13.4 82.0 (74.5-86.6)	79.6±10.9 78.0 (72.0-86.5)	82.71±13.4 81.8 (74.5-86.6)	78.8±10.1 78.0 (72.0-86.5)
Body mass index (kg·m ⁻²)	28.5±4.4 27.5 (26.2-29.2)	27.3±3.5 26.8 (24.5-28.7)	28.9±4.5 27.8 (26.2-30.9)	26.8±3.0 * 26.6 (24.4-28.1)*
Medications (number)	6.3±2.4	4.3±2.63 †	6.5±2.2	3.9±2.5 #
Fat percentage of body mass (%)	25.3±4.9	24.0±6.3	25.8±5.6	23.4±6.6
Left handgrip strength (kg)	35.3±7.8 35.0 (29.0-40.0)	38.8±10.21 36.0 (32.0-44.5)	34.6±8.6 34.0 (28.0-39.0)	39.9±9.7 * 37.5 (32.5-45.5)*
Right handgrip strength (kg)	37.8±9.2 36.5 (30.0-45.0)	39.8±10.6 37.5 (32.0-45.5)	37.1±9.1 35.5 (30.0-45.0)	40.8±10.6 38.5 (33.0-47.0)
Pmax (W·kg ⁻¹)	3.89±1.45	4.31±1.48	3.84±1.40	4.42±1.49
Uopt (rep/min)	76.4±16.7 78.1 (66.7-85.7)	79.7±13.3 81.2 (70.6-89.4)	75.7±17.5	80.8±11.4
ACE activity (U L ⁻¹)	40.0±22.2 39.3 (23.8-54.1)	55.0±30.0 * 46.1 (32.4-66.2)*	47.9±28.8 44.1 (26.0-56.9)	51.6±28.2 44.0 (31.3-65.6)
ADL	5.6±0.8 6.0 (5.5-6.0)	5.7±0.6 6.0 (6.0-6.0)	5.6±0.09 6.0 (5.5-6.0)	5.8±0.4 6.0 (6.0-6.0)
IADL	7.6±1.1 8.0 (8.0-8.0)	8.0±0.1 * 8.0 (8.0-8.0)†	7.7±0.9 8.0 (8.0-8.0)	8.0±0.1 8.0 (8.0-8.0)*
TUG (s)	7.2±1.4 7.0 (6.0-8.0)	6.7±1.5 6.43 (5.7-7.4)	7.2±1.6 6.9 (6.0-8.0)	6.6±1.3 6.4 (5.7-7.4)

Note: The results for data with a normal distribution are presented as mean ±SD. The results for data without a normal distribution are presented as mean ± SD and additionally as median and quartiles

*p<0.05; †p<0.01; #p<0.001 – ACEI compared to non ACEI and ASBMs compared to non ASBMs

Abbreviations: Pmax, maximum power; Uopt, optimal shortening velocity of the knee extensor muscles; ACE, angiotensin-converting enzyme; ACEI, Angiotensin Converting Enzyme Inhibitors; ASBMs, angiotensin system blocking medications; ADL, Activities of Daily Living; IADL, Instrumental Activities of Daily Living; TUG, Timed Up and Go test; ACEI - men taking ACEI; non ACEI – men not taking ACEI; ASBMs - men taking ASBMs; non ASBMs - men not taking ASBMs

Figure 1. Correlation between ACE activity and Pmax in patients not taking ACEI.

Figure 2. Correlation between ACE activity and Uopt in patients not taking ACEI.

Table 2. Correlations between ACE activity with anthropometric data, muscle function characteristics and functional performance in men taking/not taking ACEI and taking/not taking ASBMs.

Characteristics	ACEI (n=26)	non ACEI (n=53)	ASBMs (n=34)	non ASBMs (n=45)	all (n=79)
Age (years)	Rho=0.16 P=0.4	Rho=0.38 P=0.006	Rho=0.19 P=0.27	Rho=0.38 P=0.01	Rho=0.26 P=0.02
Body mass (kg)	Rho=-0.15 P=0.45	Rho=0.17 P=0.23	Rho=-0.04 P=0.80	Rho=0.12 P=0.42	Rho=0.04 P=0.7
Body mass index (kg·m ⁻²)	Rho=0.01 P=0.95	Rho=0.10 P=0.46	Rho=0.10 P=0.56	Rho=0.04 P=0.81	Rho=0.02 P=0.84
Medications (number)	Rho=0.24 P=0.24	Rho=0.09 P=0.50	Rho=0.17 P=0.33	Rho=0.001 P=0.99	Rho=0.03 P=0.77
Fat percentage of body mass (%)	Rho=-0.21 P=0.31	Rho=0.19 P=0.19	Rho=-0.07 P=0.70	Rho=0.14 P=0.38	Rho=0.04 P=0.75
Left handgrip strength (kg)	Rho=-0.40 P=0.087	Rho=-0.22 P=0.12	Rho=-0.29 P=0.10	Rho=-0.21 P=0.18	Rho=-0.22 P=0.06
Right handgrip strength (kg)	Rho=-0.18 P=0.38	Rho=-0.14 P=0.32	Rho=-0.08 P=0.64	Rho=-0.15 P=0.32	Rho=-0.12 P=0.29
Pmax (W·kg ⁻¹)	Rho=-0.19 P=0.34	Rho=-0.29 P=0.04	Rho=-0.14 P=0.42	Rho=-0.29 P=0.06	Rho=-0.21 P=0.06
Uopt (rep/min)	Rho=-0.15 P=0.45	Rho=-0.31 p=0.03	Rho=-0.16 P=0.35	Rho=-0.31 P=0.04	Rho=-0.22 P=0.05
ADL	Rho=-0.22 P=0.27	Rho=-0.04 P=0.76	Rho=-0.18 P=0.31	Rho=-0.002 P=0.99	Rho=-0.06 P=0.58
IADL	Rho=0.06 P=0.77	Rho=-0.07 P=0.60	Rho=0.18 P=0.29	Rho=-0.09 P=0.54	Rho=0.09 P=0.42
TUG (s)	Rho=-0.04 P=0.85	Rho=-0.12 P=0.39	Rho=-0.13 P=0.46	Rho=-0.11 P=0.47	Rho=-0.13 P=0.27

Abbreviations: Pmax, maximum power; Uopt, optimal shortening velocity of the knee extensor muscles; ACE, angiotensin-converting enzyme; ACEI, Angiotensin Converting Enzyme Inhibitors; ASBMs, angiotensin system blocking medications; TUG, Timed Up and Go test; ACEI - men taking ACEI; non ACEI - men not taking ACEI; ASBMs - men taking ASBMs; non ASBMs - men not taking ASBMs

significance) and Uopt were negatively correlated with serum ACE activity (Table 2).

However, when ACE activity and age were entered into the multiple regression analyses, age was the only selected variable to determine both Pmax and Uopt.

Discussion

In this study we have shown that muscle power and muscle contraction velocity were negatively correlated with ACE activity in patients not taking ACEI and in patients not taking any ASBMs. However, taking ACEI was not consistently associated with handgrip strength, muscle power, muscle contraction velocity, and functional performance in older men of the same age and with comparable anthropometric parameters.

In 2002, Onder *et al.*⁷ published an article suggesting that treatment with ACEI may be associated with slower decline in muscle strength and function in older women with hypertension. During the three-year observation the reduction in the muscle strength of the knee extensors and in walking speed was significantly lower in women who continuously used ACEI than in those who used other or did not use any hypertensives. Buford *et al.* also reported greater exercise-derived improvements in physical function for older ACEI users²⁴. In EELO Project, taking medicines modulating the effect of angiotensin II (both ACEI and angiotensin receptors blockers) was connected with better functional capacity and muscle strength in people over 60 year of age²⁵. In the present study, despite the fact that patients receiving any ASBMs were more than two years older than those who did not take ASBMs, they did not differ in terms of muscle power and Uopt. This is consistent with our last study in older women¹⁴. Women taking ACEI were almost two years older, had lower health status than women not taking ACEI, but these two groups did not differ in terms of handgrip strength, Pmax, Uopt and functional performance. These results may suggest effect of RAS system on muscle performance.

However, there are some studies which do not confirm clearly the protective effect of ACEI on muscle and functional performance and on improvement of the response to exercises training. Sumukadas *et al.*²⁶ did not find effects of ACEI therapy on functional status as well as on improvement in handgrip and quadriceps muscle strength in older people undergoing 20-week progressive exercise training in comparison with placebo. In nine-month follow-ups taking ACEI was connected with decreasing of ACE activity but there was no association between the changes in ACE activity and changes in muscle strength or functional capacity in older community dwelling subjects²⁷. Similarly, in the TRAIN study, the authors did not observe significant modifications in physical performance and handgrip strength after six-months of fosinopril use in older persons with high cardiovascular risk profile²⁸. In 4.4 years, a follow-up study²⁹ taking any from cardiovascular drugs (ACEI, statins or thiazides) was not associated with differences in handgrip strength decline in healthy older people.

Therefore, the results regarding the relationship between ACEI and maintaining/improving muscle mass and strength in older age are still inconsistent. Many additional factors can potentially influence this relationship, like concomitant diseases, the type and dosage of the drugs, genetic predisposition, lifestyle, etc. The key point may be the observation time. The longest period of observations mentioned above was 4.4 years²⁹, but some of them were shorter - even six months²⁸. Decreasing muscle mass and function is not a rapid process. It has been reported that the strength loss in older men is 2–3.4% per year and is modulated by some other factors³⁰. Moreover, in one observation 15% of subjects older than 60 did not at all decline handgrip strength during the average nine-year follow-up³¹. Therefore, taking ACEI may be too weak a factor to notice its impact on maintaining muscle mass and function in a relatively short period of time and a longer follow-up is needed to confirm the importance of ACEI in this area.

This seems also likely in the context of our research. The main effect of ACEI use is the decrease of ACE activity⁸. Our results show that men with higher serum ACE activity are characterized by lower Pmax as well as lower Uopt. These correlations apply only to groups of patients not taking ACEI, not taking any ASBMs and all studied men, but not men taking ACEI or ASBMs. In men taking ACEI or other ASBMs in whom pharmacotherapy modulated ACE activity, this relationship is not clear. We also did not observe a similar relationship in relation to the handgrip strength. Interestingly, even if the relationships between ACE activity and muscle function (strength, power, contraction velocity) did not reach statistical significance, the direction of the association has always been the same - lower ACE activity was associated with better muscle function. This observation applies to all indicators of muscle function and to all analyzed patients' subgroups in both our latest¹⁴ and current study. Statistically significant dependence in our last work in older women was demonstrated only for ACE activity and Uopt¹⁴. In the current study, in addition to Uopt also Pmax is negatively correlated with ACE activity, but handgrip strength is not. Uopt may be a more sensitive indicator of muscle function than strength and Pmax (force and velocity indicator), decreases with age faster than strength¹³. Our male group is older than previous group of women. Therefore, higher ACE activity had a chance to have a longer impact on the muscles. In both male groups (taking and not taking ACEI) higher ACE activity was also seen as compared to women.

This data seems also consistent with studies based on genetic tests. Serum ACE concentration is genetically determined (an insertion/deletion – I/D polymorphism in the ACE gene)⁹, so depending on the genetic predisposition, reduced or increased ACE activity has been acting on the studied men for their entire life. ACE genotype and activity may be not related to muscle function tests in young subjects³². In contrast, among older people deletion polymorphism of ACE gene (DD), connected with higher level of angiotensin II, was associated with

low muscle mass³³. Similarly, advanced cancer patients with DD ACE gene polymorphism were characterized by higher serum ACE activity but lower hand grip strength compared with ACE insertion group^{34,35}.

There are several mechanisms that can explain the effects of ACE activity on Uopt and Pmax. ACE is responsible for the conversion of angiotensin I (ang-I) to angiotensin II (ang-II). Ang-II has vasoconstrictor effect, may decrease muscle blood flow and impair the delivery of insulin and glucose to skeletal muscle. The hyper-activity of RAS system may be therefore associated with tissue insulin resistance³⁶. In addition it may also stimulate mitochondrial dysfunction, oxidative stress, and promote inflammatory processes³⁶ what may be connected with muscle atrophy. Ang-II also induces protein degradation through reactive oxygen species accumulation³⁶. Thus, lower ACE activity may limit muscle atrophy and the associated decline in muscle function (strength, power, contraction velocity). Lower ACE activity also have a neuroprotective effect^{37,38} what is crucial because neural mechanisms are important factors in the development of sarcopenia³⁹.

Conditions such as heart failure, renal failure, chronic obstructive pulmonary disease, and cancer are associated with increased activation of the RAS pathway. These conditions can contribute to muscle atrophy, and thus also the decline in muscle function³⁶.

Since ACE activity in our study was positively correlated with age, we decided to conduct multiple regression analyses for determinants of both Pmax and Uopt including ACE activity and age as independent variables. In these analyses age was the only selected variable determining Pmax and Uopt. The positive relationship between ACE activity and age was surprising, but there were no studies in such advanced age so far. In a few works on this subject, serum ACE activity increased with age in children up to 18 years old⁴⁰ but did not vary with age in adults^{41,42} or even decreased in rats⁴³ and in adult men⁴⁴.

Limitation of the study

This study has some limitations. First, the ACEI intake period was not analyzed. We only recorded taking or not taking ACEI and other medications. Therefore, it is worth conducting research taking into account the time of taking medications, because the duration of the effect of drugs on the muscles may be important in this case.

When interpreting the data, it should be taken into account that men taking ACEI took more medications and performed worse in the assessment of functional status in the IADL scale. This may indicate the poorer health status of these men and affect the interpretation of the results related to muscle function (muscle function may be determined by health status not only by ACE level). On the other hand, the relationship between serum ACE levels and muscle function occurred only in the non-ACEI group, i.e. in the group in which the drugs did not modify ACE levels. Finally, due to the size of the group and the limitations mentioned above, this work should be regarded as preliminary results that require further research, given the potential role of ACE in aging.

Conclusions

Serum ACE activity negatively determines muscle power and muscle contraction velocity but not muscle strength in older men. The issues related to the impact of taking ACEI on the maintenance of muscle function and functional performance in older man require further studies with long-term follow-up, and determining the type and dose of the treatment.

Data availability

Underlying data

Zenodo: Quadriceps muscle power and optimal shortening velocity are inversely related to angiotensin converting enzyme activity in older men, <http://doi.org/10.5281/zenodo.4493095>⁴⁵.

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](#) (CC-BY 4.0).

References

1. Cléménçon M, Hautier CA, Rahmani A, *et al.*: **Potential role of optimal velocity as a qualitative factor of physical functional performance in women aged 72 to 96 years.** *Arch Phys Med Rehabil.* 2008; **89**(8): 1594–1599. [PubMed Abstract](#) | [Publisher Full Text](#)
2. Kostka JS, Czernicki JW, Kostka TJ: **Association of muscle strength, power, and optimal shortening velocity with functional abilities of women with chronic osteoarthritis participating in a multi-modal exercise program.** *J Aging Phys Act.* 2014; **22**(4): 564–570. [PubMed Abstract](#) | [Publisher Full Text](#)
3. Bahat G, Tufan A, Kilic C, *et al.*: **Prevalence of sarcopenia and its components in community-dwelling outpatient older adults and their relation with functionality.** *Aging Male.* 2020; **23**(5): 424–430. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Sgrò P, Sansone M, Sansone A, *et al.*: **Physical exercise, nutrition and hormones: three pillars to fight sarcopenia.** *Aging Male.* 2019; **22**(2): 75–88. [PubMed Abstract](#) | [Publisher Full Text](#)
5. de Spiegeleer A, Beckwée D, Bautmans I, *et al.*: **Pharmacological Interventions to Improve Muscle Mass, Muscle Strength and Physical Performance in Older People: An Umbrella Review of Systematic Reviews and Meta-analyses.** *Drugs Aging.* 2018; **35**(8): 719–734. [PubMed Abstract](#) | [Publisher Full Text](#)
6. Ferrari R, Guardigli G, Ceconi C: **Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium.** *Cardiovasc Drugs Ther.* 2010; **24**(4): 331–339. [PubMed Abstract](#) | [Publisher Full Text](#)
7. Onder G, Penninx BWJH, Balkrishnan R, *et al.*: **Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study.** *Lancet.* 2002; **359**(9310): 926–930. [PubMed Abstract](#) | [Publisher Full Text](#)
8. Krasowski MD, Savage J, Ehlers A, *et al.*: **Ordering of the Serum Angiotensin-Converting Enzyme Test in Patients Receiving Angiotensin-Converting**

- Enzyme Inhibitor Therapy: An Avoidable but Common Error.** *Chest.* 2015; **148**(6): 1447–1453.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Nakai K, Itoh C, Miura Y, *et al.*: **Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese.** *Circulation.* 1994; **90**(5): 2199–2202.
[PubMed Abstract](#) | [Publisher Full Text](#)
 10. Nazarov IB, Woods DR, Montgomery HE, *et al.*: **The angiotensin converting enzyme I/D polymorphism in Russian athletes.** *Eur J Hum Genet.* 2001; **9**(10): 797–801.
[PubMed Abstract](#) | [Publisher Full Text](#)
 11. Yoshida T, Tabony AM, Galvez S, *et al.*: **Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia.** *Int J Biochem Cell Biol.* 2013; **45**(10): 2322–2332.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 12. Williams AG, Day SH, Folland JP, *et al.*: **Circulating angiotensin converting enzyme activity is correlated with muscle strength.** *Med Sci Sports Exerc.* 2005; **37**(6): 944–948.
[PubMed Abstract](#)
 13. Metter EJ, Conwit R, Tobin J, *et al.*: **Age-associated loss of power and strength in the upper extremities in women and men.** *J Gerontol A Biol Sci Med Sci.* 1997; **52**(5): B267–276.
[PubMed Abstract](#) | [Publisher Full Text](#)
 14. Kostka J, Sikora J, Kostka T: **Relationship of quadriceps muscle power and optimal shortening velocity with angiotensin-converting enzyme activity in older women.** *Clin Interv Aging.* 2017; **12**: 1753–1760.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 15. Phillips SK, Rook KM, Siddle NC, *et al.*: **Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy.** *Clin Sci (Lond).* 1993; **84**(1): 95–98.
[PubMed Abstract](#) | [Publisher Full Text](#)
 16. Zhang YF, Cheng Q, Tang NLS, *et al.*: **Gender difference of serum angiotensin-converting enzyme (ACE) activity in DD genotype of ACE insertion/deletion polymorphism in elderly Chinese.** *J Renin Angiotensin Aldosterone Syst.* 2014; **15**(4): 547–552.
[PubMed Abstract](#) | [Publisher Full Text](#)
 17. Stolarz AJ, Rusch NJ: **Gender Differences in Cardiovascular Drugs.** *Cardiovasc Drugs Ther.* 2015; **29**(4): 403–410.
[PubMed Abstract](#) | [Publisher Full Text](#)
 18. Durnin JV, Womersley J: **Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years.** *Br J Nutr.* 1974; **32**(1): 77–97.
[PubMed Abstract](#) | [Publisher Full Text](#)
 19. Rantanen T, Guralnik JM, Foley D, *et al.*: **Midlife hand grip strength as a predictor of old age disability.** *JAMA.* 1999; **281**(6): 558–560.
[PubMed Abstract](#) | [Publisher Full Text](#)
 20. Kozicka I, Kostka T: **Handgrip strength, quadriceps muscle power, and optimal shortening velocity roles in maintaining functional abilities in older adults living in a long-term care home: a 1-year follow-up study.** *Clin Interv Aging.* 2016; **11**(11): 739–747.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 21. Katz S, Ford AB, Moskowitz RW, *et al.*: **Studies of illness in the aged. the index of ADL: a standardized measure of biological and psychosocial function.** *JAMA.* 1963; **185**: 914–919.
[PubMed Abstract](#) | [Publisher Full Text](#)
 22. Lawton MP, Brody EM: **Assessment of older people: self-maintaining and instrumental activities of daily living.** *Gerontologist.* 1969; **9**(3): 179–186.
[PubMed Abstract](#) | [Publisher Full Text](#)
 23. Podsiadlo D, Richardson S: **The timed “up & go”: a test of basic functional mobility for frail elderly persons.** *J Am Geriatr Soc.* 1991; **39**(2): 142–148.
[PubMed Abstract](#) | [Publisher Full Text](#)
 24. Buford TW, Manini TM, Hsu FC, *et al.*: **Angiotensin-converting enzyme inhibitor use by older adults is associated with greater functional responses to exercise.** *J Am Geriatr Soc.* 2012; **60**(7): 1244–1252.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 25. Coelho VA, Probst VS, Nogari BM, *et al.*: **Angiotensin-II blockage, muscle strength, and exercise capacity in physically independent older adults.** *J Phys Ther Sci.* 2016; **28**(2): 547–552.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 26. Sumukadas D, Band M, Miller S, *et al.*: **Do ACE inhibitors improve the response to exercise training in functionally impaired older adults? A randomized controlled trial.** *J Gerontol A Biol Sci Med Sci.* 2014; **69**(6): 736–743.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 27. Bunout D, Barrera G, de la Maza MP, *et al.*: **Effects of enalapril or nifedipine on muscle strength or functional capacity in elderly subjects. A double blind trial.** *J Renin Angiotensin Aldosterone Syst.* 2009; **10**(2): 77–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Cesari M, Pedone C, Incalzi RA, *et al.*: **ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study.** *J Am Med Dir Assoc.* 2010; **11**(1): 26–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 29. Witham MD, Syddall HE, Dennison E, *et al.*: **ACE inhibitors, statins and thiazides: no association with change in grip strength among community dwelling older men and women from the Hertfordshire Cohort Study.** *Age Ageing.* 2014; **43**(5): 661–666.
[PubMed Abstract](#) | [Publisher Full Text](#)
 30. Forrest KYZ, Zmuda JM, Cauley JA: **Patterns and determinants of muscle strength change with aging in older men.** *Aging Male.* 2005; **8**(3–4): 151–156.
[PubMed Abstract](#) | [Publisher Full Text](#)
 31. Kallman DA, Plato CC, Tobin JD: **The role of muscle loss in the age-related decline of grip strength: cross-sectional and longitudinal perspectives.** *J Gerontol.* 1990; **45**(3): M82–88.
[PubMed Abstract](#) | [Publisher Full Text](#)
 32. McCauley T, Mastana SS, Hossack J, *et al.*: **Human angiotensin-converting enzyme I/D and alpha-actinin 3 R577X genotypes and muscle functional and contractile properties.** *Exp Physiol.* 2009; **94**(1): 81–89.
[PubMed Abstract](#) | [Publisher Full Text](#)
 33. Handayani MDN, Sadewa AH, Farmawati A, *et al.*: **Deletion Polymorphism of Angiotensin-Converting Enzyme Gene Is Associated with Low Muscle Mass in Elderly People in Jakarta, Indonesia.** *Kobe J Med Sci.* 2018; **64**(3): E119–E125.
[PubMed Abstract](#) | [Free Full Text](#)
 34. Vigano A, Trutschnigg B, Kilgour RD, *et al.*: **Relationship between angiotensin-converting enzyme gene polymorphism and body composition, functional performance, and blood biomarkers in advanced cancer patients.** *Clin Cancer Res.* 2009; **15**(7): 2442–2447.
[PubMed Abstract](#) | [Publisher Full Text](#)
 35. Kang HJ, Kim CH, Park DS, *et al.*: **The Impacts of ACE Activity according to ACE I/D Polymorphisms on Muscular Functions of People Aged 65.** *Ann Rehabil Med.* 2012; **36**(4): 433–446.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 36. Cabello-Verrugio C, Morales MG, Rivera JC, *et al.*: **Renin-angiotensin system: an old player with novel functions in skeletal muscle.** *Med Res Rev.* 2015; **35**(3): 437–463.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. Hanif K, Bid HK, Konwar R: **Reinventing the ACE inhibitors: some old and new implications of ACE inhibition.** *Hypertens Res.* 2010; **33**(1): 11–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
 38. Mansoor Q, Javaid A, Bilal N, *et al.*: **Angiotensin-converting enzyme (ACE) gene II genotype protects against the development of diabetic peripheral neuropathy in type 2 diabetes mellitus.** *J Diabetes.* 2012; **4**(3): 257–261.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Kwon YN, Yoon SS: **Sarcopenia: Neurological Point of View.** *J Bone Metab.* 2017; **24**(2): 83–89.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 40. Bénétteau-Burnat B, Baudin B, Morgant G, *et al.*: **Serum angiotensin-converting enzyme in healthy and sarcoidotic children: comparison with the reference interval for adults.** *Clin Chem.* 1990; **36**(2): 344–346.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. Faure-Delanef L, Baudin B, Bénétteau-Burnat B, *et al.*: **Plasma concentration, kinetic constants, and gene polymorphism of angiotensin I-converting enzyme in centenarians.** *Clin Chem.* 1998; **44**(10): 2083–2087.
[PubMed Abstract](#) | [Publisher Full Text](#)
 42. Zdrojewicz Z: **[Does the activity of angiotensin converting enzyme depend on sex, age, body weight and phase of the menstruation cycle in women?]** *Pol Tyg Lek.* 1992; **47**(44–45): 1016–1017.
[PubMed Abstract](#)
 43. Challah M, Nadaud S, Philippe M, *et al.*: **Circulating and cellular markers of endothelial dysfunction with aging in rats.** *Am J Physiol.* 1997; **273**(4): H1941–1948.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Fernández-Atucha A, Izaguirre A, Fraile-Bermúdez AB, *et al.*: **Sex differences in the aging pattern of renin-angiotensin system serum peptidases.** *Biol Sex Differ.* 2017; **8**: 5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 45. Kostka J, Sikora J, Guligowska A, *et al.*: **Quadriceps muscle power and optimal shortening velocity are inversely related to angiotensin converting enzyme activity in older men.** [Data set]. *Zenodo.* 2021.
<http://www.doi.org/10.5281/zenodo.4493095>

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 16 July 2021

<https://doi.org/10.5256/f1000research.57350.r87203>

© 2021 Hautier C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Christophe A. Hautier

Laboratoire Interuniversitaire de Biologie de la Motricité, Université Claude Bernard Lyon 1, Villeurbanne, France

I think this article has been greatly improved, especially with the addition of the limitations part and with the appropriate details on the methodology.

I think it can be indexed as is because although the conclusions are still a bit speculative, the subject and the approach deserve to be developed in future studies.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Sport Sciences, physiology, biomechanics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 17 May 2021

<https://doi.org/10.5256/f1000research.54351.r81773>

© 2021 Hautier C. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Christophe A. Hautier

Laboratoire Interuniversitaire de Biologie de la Motricité, Université Claude Bernard Lyon 1, Villeurbanne, France

This article focused about the effects of angiotensin Converting Enzyme Inhibitors (ACEI) and other angiotensin system blocking medications (ASBMs) on the strength and speed capacities of the skeletal muscle in the elderly. The subject is remarkably interesting in the prevention of dependence in the elderly because the means of combating sarcopenia and dynapenia are still poorly understood. Of course, exercise and diet have a significant effect on the muscle mass and strength and functionality of the elderly, on the other hand it seems interesting to continue to look for medicinal methods that can help maintain autonomy.

Seventy-nine elderly men took part in the study, which is still an interesting sample and suggests that the results can be extrapolated to a larger population. Positive relationship between age and ACE activity was demonstrated and, relatively weak negative correlations were observed between ACE activity and Maximum Power or optimal speed. However, taking Angiotensin Converting Enzyme Inhibitors (ACEI) did not modify muscle performance in this population.

This article is well written however, the rationale of taking converting Enzyme Inhibitors (ACEI) to maintain muscle mass and strength should be reinforced with some mechanistic hypotheses. Even if the authors previously published an article about the relationship of quadriceps muscle power and optimal shortening velocity with angiotensin-converting enzyme activity in older women, there is only indirect evidence generally associating the functional status of the senior and ACE activity.

The method of constituting the groups of subjects (ACEI vs non ACEI and ASBMs vs non ASBMs) is not presented and moreover the different categories appear only in the results and not in the method. This seems to be an important limitation of this work, for interpreting differences in strength and/or BMI. I think it can be improved a lot by better explaining the constitution of groups in the method part. The fact that patients taking ACEI took more medications and were characterized by lower level of ACE in blood samples and lower IADL status is a major concern that should be better discussed in the limitations of the study. Nevertheless, the correlations are interesting and provide additional evidence about the significance of ACE in ageing.

I think it is necessary to do a paragraph on the limitations of the study and better discuss the fact that these results are a bit like preliminary results that require further study given the potential role of ACE in aging. I would have liked the authors to touch very lightly on the mechanistic assumptions that might explain the effects of ACE on optimal speed and maximum power. These hypotheses are they neuromuscular, systemic, cardiovascular or else indirect because of the improvement in the quality of life and spontaneous activity. I do not think the authors can conclude on the ineffectiveness of taking ACEI in maintaining functional performance in older men.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

No

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

No

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Sport Sciences, physiology, biomechanics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 28 May 2021

Joanna Kostka, Medical University of Lodz, Lodz, Poland

Dear Reviewer,

We would like to thank you for the analysis of this manuscript and your valuable remarks. The manuscript has been corrected according to the comments. All changes are described below:

1: *"This article is well written however, the rationale of taking converting Enzyme Inhibitors (ACEI) to maintain muscle mass and strength should be reinforced with some mechanistic hypotheses. Even if the authors previously published an article about the relationship of quadriceps muscle power and optimal shortening velocity with angiotensin-converting enzyme activity in older women, there is only indirect evidence generally associating the functional status of the senior and ACE activity."*

Answer: We supplemented the Introduction section with suggested information: The authors of the article explain this effect with several mechanisms, such as: direct influence on mechanical and metabolic changes in muscles (shift of the myosin heavy chains of skeletal muscle toward the fatigue-resistant forms; increasing insulin sensitivity, glycogen storage and glucose uptake in skeletal muscle; reduction of kinin breakdown and, consequently, improved circulation and better glucose and amino acid uptake), suppression of inflammatory activation connected with muscle catabolism, beneficial effect on the nutritional status (inhibition of interleukin-6, which, among others, reduces appetite and, consequently, may cause malnutrition).

2: *"The method of constituting the groups of subjects (ACEI vs non ACEI and ASBMs vs non ASBMs)"*

is not presented and moreover the different categories appear only in the results and not in the method. This seems to be an important limitation of this work, for interpreting differences in strength and/or BMI. I think it can be improved a lot by better explaining the constitution of groups in the method part."

Answer: Suggested information has been added to the "Methods" section:

Based on the analysis of medications taken, men were assigned to the following groups: ACEI - if they were taking any medications belonging to the ACEI group (n = 26) and to the non ACEI group - if they were not taking ACEI (n = 53). Similarly, if men were taking any drugs from the angiotensin system blocking medications (ASBMs) group, they were assigned to the ASBMs group (n = 34), if not, then to the non ASBMs group (n = 45).

3. *"The fact that patients taking ACEI took more medications and were characterized by lower level of ACE in blood samples and lower IADL status is a major concern that should be better discussed in the limitations of the study."*

Answer: This problem is discussed in the section "Limitation of the study" as suggested.

4. *"I think it is necessary to do a paragraph on the limitations of the study and better discuss the fact that these results are a bit like preliminary results that require further study given the potential role of ACE in aging."*

Answer: A "Limitation of the study" section was added to the discussion.

Limitation of the study

This study has some limitations. First, the ACEI intake period was not analyzed. We only recorded taking or not taking ACEI and other medications. Therefore, it is worth conducting research taking into account the time of taking medications, because the duration of the effect of drugs on the muscles may be important in this case.

When interpreting the data, it should be taken into account that men taking ACEI took more medications and performed worse in the assessment of functional status in the IADL scale. This may indicate the poorer health status of these men and affect the interpretation of the results related to muscle function (muscle function may be determined by health status not only by ACE level). On the other hand, the relationship between serum ACE levels and muscle function occurred only in the non-ACEI group, i.e. in the group in which the drugs did not modify ACE levels. Finally, due to the size of the group and the limitations mentioned above, this work should be regarded as preliminary results that require further research, given the potential role of ACEs in aging.

5. *"I would have liked the authors to touch very lightly on the mechanistic assumptions that might explain the effects of ACE on optimal speed and maximum power. These hypotheses are they neuromuscular, systemic, cardiovascular or else indirect because of the improvement in the quality of life and spontaneous activity."*

Answer: We slightly modified and expanded part of the discussion on this topic:

There are several mechanisms that can explain the effects of ACE activity on Uopt and Pmax potentially affecting muscle function that are associated with an increased ACE activity, and thus with the hyper-activity of the RAS system. ACE is responsible for the conversion of

angiotensin I (ang-I) to angiotensin II (ang-II). Ang-II has vasoconstrictor effect, may decrease muscle blood flow and impair the delivery of insulin and glucose to skeletal muscle. The hyper-activity of RAS system may be therefore associated with tissue insulin resistance³⁶, muscle atrophy, and fibrosis. RAS In addition it may also stimulate mitochondrial dysfunction, oxidative stress, and promote inflammatory processes³⁶ what may be connected with muscle atrophy. Ang-II also induces protein degradation through reactive oxygen species accumulation³⁶. Thus, lower ACE activity may limit muscle atrophy and the associated decline in muscle function (strength, power, contraction velocity). Lower ACE activity may also have a neuroprotective effect^{37, 38} what is crucial because neural mechanisms are important factors in the development of sarcopenia³⁹. Conditions such as heart failure, renal failure, chronic obstructive pulmonary disease, and cancer are associated with increased activation of the RAS pathway. These conditions can contribute to muscle atrophy, and thus also the decline in muscle function³⁶.

6. *"I do not think the authors can conclude on the ineffectiveness of taking ACEI in maintaining functional performance in older men."*

Answer: We modified the conclusions (also in the abstract):

The issues related to the impact of taking ACEI on the maintenance of muscle function and functional performance in older man require further studies with long-term follow-up, and determining the type and dose of the treatment.

Best regards
Joanna Kostka

Competing Interests: No competing interests were disclosed.

Reviewer Report 29 March 2021

<https://doi.org/10.5256/f1000research.54351.r81534>

© 2021 Wiszomirska I. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Ida Wiszomirska

Faculty of Rehabilitation, Józef Piłsudski University of Physical Education, Warsaw, Poland

Review of the article "Quadriceps muscle power and optimal shortening velocity are inversely related to angiotensin-converting enzyme activity in older men."

The topic undertaken in this article is important. Aging is associated with a gradual loss of muscle function and, consequently, deterioration of functional efficiency. Identification of factors that could slow down this process may contribute to the improvement of the functioning of the elderly.

Introduction

The introductory part contains a factual and correct justification of the topic undertaken in the study, taking into account correctly selected items of the literature. The objectives of the work formulated correctly.

One sentence requires an explanation:

- *"Taking ACEI as well as the ACE genotype with insertion (II) of allele in gene, is associated with lower serum ACE activity and with predispositions for practicing some sports."* – there is no evidence, that taking ACEI is associated with predispositions for practicing some sports (in fact, there are some reports about the ACE genotype) - this sentence suggests such a relationship. Please formulate this sentence in a different way.

Methodology

Methodology is generally well described, but it is worth supplementing some information:

- Please add "for each hand separately" to the sentence *"A better record was used for analysis"* (last sentence of the section *"Muscle strength"*).
- Despite the reference to the literature, in this part it is worth describing the measurement of Pmax and Uopt in a little more detail.

Results are shown as a text, in tables and in 2 figures. This section is presented clearly.

In the discussion, the results of own research were compared to the current literature. In this section, it is worth discussing the limitations of the study. Correctly formulated conclusions.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Physiotherapy, Physical Rehabilitation, Muscle Function

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 28 May 2021

Joanna Kostka, Medical University of Lodz, Lodz, Poland

Dear Reviewer,

We would like to thank you for the analysis of this manuscript and your valuable remarks. The manuscript has been corrected according to the comments. All changes are described below.

1. One sentence requires an explanation:

"Taking ACEI as well as the ACE genotype with insertion (II) of allele in gene, is associated with lower serum ACE activity and with predispositions for practicing some sports." – there is no evidence, that taking ACEI is associated with predispositions for practicing some sports (in fact, there are some reports about the ACE genotype) - this sentence suggests such a relationship. Please formulate this sentence in a different way.

Answer: This sentence was modified to:

"Taking ACEI as well as the ACE genotype with insertion (II) of allele in gene, is associated with lower serum ACE activity^{8,9}. There are suggestions that the ACE genotype type predisposes one to be successful in certain sports¹⁰."

2. Methodology

Please add "for each hand separately" to the sentence "A better record was used for analysis" (last sentence of the section "Muscle strength").

Answer: We have added this sentence in line with the Reviewer's comment.

3. Despite the reference to the literature, in this part it is worth describing the measurement of Pmax and Uopt in a little more detail.

Answer: The description of the Pmax and Uopt measurement methodology has been supplemented:

"Muscle power and optimal shortening velocity evaluations were performed with especially prepared ergometer (Monark type 818E Stockholm, Sweden), during two 8-second attempts to pedal at the maximum possible speed with friction loads of $0.25 \text{ N}\cdot\text{kg}^{-1}$ and $0.35 \text{ N}\cdot\text{kg}^{-1}$ of body mass. Instantaneous pedaling velocity (U), force (F) and power output (P) were calculated each 5ms and then averaged over each downstroke period. The highest value of P (maximal short-term power – Pmax) and optimal shortening velocity (Uopt - velocity at which the power reaches a maximum value) were calculated from a 3rd order polynomial function. The methodology ..."

4. Discussion

In this section, it is worth discussing the limitations of the study.

Answer: A "limitation of the study" section was added to the discussion.

Best regards
Joanna Kostka

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research